SEARCH

SEARCH BY CITATION

References

  • 1
    Gschwind A, Fischer OM & Ullrich A (2004) The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev 4, 361370.
  • 2
    Burgess AW, Cho H-S, Elgenblot C, Ferguson KM, Garrett TPJ, Leahy DJ, Lemmon MA, Siwkowski MX, Ward CW & Yokoyama S (2003) An open-and -shut case? Recent insights into the activation of EGF/ErbB receptors Mol Cell 12, 541552.
  • 3
    Hynes NE & Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev 5, 341354.
  • 4
    Schneider MR & Wolf E (2009) The epidermal growth factor receptor ligands at a glance. J Cell Physiol 218, 460466.
  • 5
    Zhang X, Gureasko J, Shen K, Cole PA & Kuriyan J (2006) An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125, 11371149.
  • 6
    Voldborg BR, Damstrup L, Spang-Thomsen M & Poulsen HS (1997) Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 8, 11971206.
  • 7
    Ji H, Zhao X, Yuza Y, Shimamura T, Li D, Protopopov A, Jung BL, McNamara K, Xia H, Glatt KA et al. (2006) Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci USA 103, 78177822.
  • 8
    Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, DeBiasi RM, Yoshimoto K, King JC, Nghiemphu P, Yuza Y et al. (2006) Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med 3, e485.
  • 9
    Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350, 21292139.
  • 10
    Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (New York, NY) 304, 14971500.
  • 11
    Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L et al. (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101, 1330613311.
  • 12
    Mitsudomi T & Yatabe Y (2007) Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98, 18171824.
  • 13
    Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T & Mitsudomi T (2004) Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64, 89198923.
  • 14
    Matsuo K, Ito H, Yatabe Y, Hiraki A, Hirose K, Wakai K, Kosaka T, Suzuki T, Tajima K & Mitsudomi T (2006) Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese. Cancer Sci 98, 96101.
  • 15
    Miller VA, Kris MG, Shah N, Patel J, Azzoli C, Gomez J, Krug LM, Pao W, Rizvi N, Pizzo B et al. (2004) Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22, 11031109.
  • 16
    Yatabe Y, Mitsudomi T & Takahashi T (2002) TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol 26, 767773.
  • 17
    Yatabe Y, Kosaka T, Takahashi T & Mitsudomi T (2005) EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol 29, 633639.
  • 18
    Sordella R, Bell DW, Haber DA & Settleman J (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science (New York, NY) 305, 11631167.
  • 19
    Greulich H, Chen T-H, Feng W, Janne PA, Alvarez JV, Bulmer SE, Zappaterra M, Frank DA, Hahn WC, Sellers WR et al. (2005) Oncogenic transformation by inhibitor-sensitive and resistant EGFR mutations. PLoS Med 2, e313.
  • 20
    Carey KD, Garton AJ, Romero MS, Kahler J, Thomson S, Ross S, Park F, Haley JD, Gibson N & Sliwkowski MX (2006) Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res 66, 81638171.
  • 21
    Mulloy R, Ferrand A, Kim Y, Sordella R, Bell DW, Haber DA, Anderson KS & Settleman J (2007) Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res 67, 23252330.
  • 22
    Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, Mahmood U, Mitchell A, Sun Y, Al-Hashem R et al. (2006) The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9, 485495.
  • 23
    Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W & Varmus HE (2006) Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 20, 14961510.
  • 24
    Yatabe Y, Takahashi T & Mitsudomi T (2008) Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. Cancer Res 68, 21062111.
  • 25
    Slebos RJ, Kibbelaar RE, Dalesio O, Kooistra A, Stam J, Meijer CJ, Wagenaar SS, Vanderschueren RG, van Zandwijk N, Mooi WJ et al. (1990) K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323, 561565.
  • 26
    Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, Lee H, Wistuba II, Fong KM, Toyooka S, Shimizu N et al. (2005) Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 65, 16421646.
  • 27
    Han SW, Kim TY, Jeon YK, Hwang PG, Im SA, Lee KH, Kim JH, Kim DW, Heo DS, Kim NK et al. (2006) Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res 12, 25382544.
  • 28
    Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara SI, Watanabe H, Kurashina K, Hatanaka H et al. (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561566.
  • 29
    Inamura K, Takeuchi K, Togashi Y, Hatano S, Ninomiya H, Motoi N, Mun MY, Sakao Y, Okumura S, Nakagawa K et al. (2009) EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 22, 508515.